Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remsima SC Monotherapy vs Combination Therapy in Crohn's Disease
NCT06059989Phase 3Recruiting
- Sponsor
- University of Amsterdam
- Start
- Nov 2021
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in Crohn's disease, sponsored by University of Amsterdam. Started Nov 2021; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06059989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059989.